Innate Pharmaceuticals AB

SE-903 47 (Unknown)

Start Date End Date Funded Value Relevance

CSV

25 50 100

£250,630

Oct 06 - Apr 10

Inhibition of bacterial Type III secretion by salicylanilides

BBSRC award to The Pirbright Institute and Mark Stevens

{{facetGroup.name}}

{{getFilterText(facet,showCount)}}